Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Deciphering tumor response to CD47 inhibition to inform effective strategies for CD47 blockade in lung cancer

FY 2023-24

Summary
Lung cancer is the leading cause of cancer death in Canada. While there have been advances in therapies to treat lung cancer, high rates of drug resistance and tumor recurrence emphasize the need for new therapeutic strategies. Immunotherapy is a type of treatment designed to re-activate a patient's immune system to attack and kill tumor cells. It works because some tumors suppress the immune system to prevent it from killing them. Studies have shown that lung cancers often upregulate a cell surface protein called CD47 to de-activate the immune system and enable their survival. In normal cells, CD47 acts as a "don't eat me" signal to prevent unwanted immune responses against healthy cells. Thus, by expressing CD47, lung cancer cells can avoid being eaten and destroyed by the immune system. CD47 blockade is a new class of immunotherapy that can inhibit CD47 on cancer cells and stimulate immune cells to kill them. My research aims to determine how lung tumor response to CD47 blockade is controlled to understand how it can be used most effectively in lung cancer patients. I predict that specific genes in lung cancer cells dictate whether tumors will be sensitive or resistant to CD47 blockade. To investigate this, I will use multiple genetic approaches to identify genes that regulate response to CD47 inhibition in lung cancer models. Then I will do follow-up studies in which I turn the identified genes on or off in lung cancer cells and treat them with CD47 inhibitors to confirm that the genes regulate response to CD47 blockade. The findings from my project will reveal gene biomarkers that indicate whether a patient will respond to CD47 blockade, and genes that can be targeted in combination with CD47 inhibitors to enhance their anti-cancer effects. Ultimately, my research will inform the development of effective strategies for using CD47-targeted immunotherapy to improve lung cancer survival rates in Canada and worldwide.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
496498
Name
Lau Asa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Deciphering tumor response to CD47 inhibition to inform effective strategies for CD47 blockade in lung cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarker Discovery; Cd47; Crispr Screens; Functional Genomics; Immune Checkpoint Blockade; Immunotherapy; Lung Cancer; Transcriptomic Profiling
Abstract
Lung cancer is the leading cause of cancer death in Canada. While there have been advances in therapies to treat lung cancer, high rates of drug resistance and tumor recurrence emphasize the need for new therapeutic strategies. Immunotherapy is a type of treatment designed to re-activate a patient's immune system to attack and kill tumor cells. It works because some tumors suppress the immune system to prevent it from killing them. Studies have shown that lung cancers often upregulate a cell surface protein called CD47 to de-activate the immune system and enable their survival. In normal cells, CD47 acts as a "don't eat me" signal to prevent unwanted immune responses against healthy cells. Thus, by expressing CD47, lung cancer cells can avoid being eaten and destroyed by the immune system. CD47 blockade is a new class of immunotherapy that can inhibit CD47 on cancer cells and stimulate immune cells to kill them. My research aims to determine how lung tumor response to CD47 blockade is controlled to understand how it can be used most effectively in lung cancer patients. I predict that specific genes in lung cancer cells dictate whether tumors will be sensitive or resistant to CD47 blockade. To investigate this, I will use multiple genetic approaches to identify genes that regulate response to CD47 inhibition in lung cancer models. Then I will do follow-up studies in which I turn the identified genes on or off in lung cancer cells and treat them with CD47 inhibitors to confirm that the genes regulate response to CD47 blockade. The findings from my project will reveal gene biomarkers that indicate whether a patient will respond to CD47 blockade, and genes that can be targeted in combination with CD47 inhibitors to enhance their anti-cancer effects. Ultimately, my research will inform the development of effective strategies for using CD47-targeted immunotherapy to improve lung cancer survival rates in Canada and worldwide.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lau, Asa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~